Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donor Immunization with Myeloma Id Vaccine in Allogeneic SCT
NCT00006184Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2001
- Primary completion
- Jan 2008
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of Myeloma Immunoglobulin Idiotype Vaccine in multiple myeloma (MM) (2 arms), sponsored by National Cancer Institute. Primary endpoints: Cellular and Humoral Immunity at 105 days and Number of Participants With Adverse Events at 9 years. Started Feb 2001; status: completed.
02
Drugs
Myeloma Immunoglobulin Idiotype Vaccine
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00006184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006184.